Eledon Pharmaceuticals to Present at H.C. Wainwright Global Life Sciences Conference
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a clinical stage biopharmaceutical company, announced that CEO David-Alexandre C. Gros, M.D. will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10. The presentation will be available on-demand starting March 9 at 7:00 am EST. Eledon focuses on developing targeted treatments for organ transplantation and immunological diseases, with its lead compound AT-1501, an anti-CD40L antibody aimed at improving immune regulation.
- None.
- None.
IRVINE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that David-Alexandre C. Gros, M.D., Eledon’s CEO, will present at the H.C. Wainwright Global Life Sciences Conference, which is being held March 9-10.
The presentation will be available on-demand to virtual conference attendees beginning on Tuesday, March 9th at 7:00 am EST.
About Eledon Pharmaceuticals and AT-1501
Eledon Pharmaceuticals (f/k/a Novus Therapeutics, Inc.) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for persons living with an autoimmune disease, persons undergoing organ or cell-based transplantation, and for persons living with ALS. The company’s lead compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which is especially important for autoimmune diseases and in the transplant setting. Furthermore AT-1501 is an IgG1 antibody specifically engineered to cripple the Fc effector function to potentially improve safety, as well as to potentially provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other approaches. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212.915.2577
Source: Eledon Pharmaceuticals, Inc.
FAQ
When will Eledon Pharmaceuticals present at the H.C. Wainwright Global Life Sciences Conference?
What time will Eledon's presentation be available on-demand?
What is AT-1501 developed by Eledon Pharmaceuticals?
What are the main focuses of Eledon Pharmaceuticals?
What are the benefits of the CD40L pathway targeted by Eledon?
